Olaparib Plus Durvalumab Show Durable Activity in Germline BRCA+ Breast, Ovarian Cancer

October 11, 2019 5:00 pm

By Wayne Kuznar

The case for the combination of olaparib (Lynparza) and durvalumab (Imfinzi) in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations was strengthened based on the updated results from the phase I/II MEDIOLA, … Read more

Ovarian Cancer Drug Misses Mark… Right?

October 1, 2019 5:00 pm

By Charles Bankhead

Anti-folate fails phase III test, but key biomarker measurement may have been faulty.

An antibody-drug conjugate (ADC) targeting folate-receptor expression failed to improve progression-free survival (PFS) versus chemotherapy in patients with recurrent platinum-resistant ovarian cancer, according to … Read more

PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Cancer?

September 29, 2019 6:00 pm

By Ed Susman

PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines.

Patients with newly diagnosed advanced ovarian cancer who responded to first-line chemotherapy, then were treated with niraparib (Zejula), had a significantly reduced risk … Read more

First-Line Combo Boosts PFS in Advanced Ovarian Cancer

September 28, 2019 5:00 pm

By Charles Bankhead

Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup.

Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab, a … Read more

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?

September 20, 2019 8:00 pm

By Dave Levitan

The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. The chemotherapy-free regimen will now be tested in a phase III … Read more

Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?

August 26, 2019 7:00 pm

By Dave Levitan

The combination of a poly (ADP-ribose) polymerase (PARP) inhibitor and immune checkpoint inhibition with tislelizumab was well tolerated and showed promising anti-tumor activity in a phase I trial of patients with multiple solid tumor types, according to … Read more

AstraZeneca’s Ovarian Cancer Drug Hits Main Goal in New Study

August 13, 2019 5:15 am

By John Lauerman

AstraZeneca Plc’s Lynparza got a boost from results of a study that may widen the drug’s use among patients with advanced ovarian cancer.

Ovarian tumor growth slowed in patients who got Lynparza in addition to a … Read more

Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer

July 23, 2019 5:00 pm

By Dave Levitan

A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers.

“Up to … Read more

The Need for Clinical Trial Navigators

June 20, 2019 5:00 pm

Our Clinical Trial Finder is a personalized and online search tool that will help you to find a clinical trial based on your location or clinical situation (i.e. platinum sensitive or platinum resistant, number of previous treatments). We can also Read more

Novel Treatment Turns Tumors Into ‘Cancer Vaccine Factories’

June 13, 2019 5:00 pm

By Mark L. Fuerst

In-situ vaccine may enhance immunotherapy response in resistant cancers, study shows.

A novel approach to cancer immunotherapy injects immune stimulants directly into a tumor to “teach,” induce the immune system to destroy the cancer and other

Read more

Trial Examines Tolerance of Maintenance Olaparib in Advanced Ovarian Cancer

June 12, 2019 5:00 pm

By Dave Levitan

An analysis of the phase III SOLO1 trial found no new safety signals when the PARP inhibitor olaparib was given as maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation. Nausea, fatigue, … Read more

SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer

June 5, 2019 8:00 pm

By Leah Lawrence

Patients with BRCA-mutated, platinum-sensitive relapsed ovarian cancer derived significant clinical benefit from treatment with olaparib monotherapy compared with treatment of physician’s choice, according to the results of the SOLO3 trial, a US Food and Drug Administration … Read more

Benefit of Single-Agent Carboplatin in Vulnerable, Elderly Patients With Ovarian Cancer

June 5, 2019 7:00 pm

By Leah Lawrence

Single-agent carboplatin conferred significantly worse survival outcomes in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer compared with weekly or every 3 weeks carboplatin/paclitaxel, according to results of the EWOC-1 trial (abstract 5508), which … Read more

Chemo-Free Combo Boosts PFS in Recurrent Ovarian Cancer

June 4, 2019 6:00 pm

By Ian Ingram

Benefit seen across all subgroups for patients with platinum-sensitive disease.

Ovarian cancer patients with recurrent, platinum-sensitive disease experienced a longer interval without disease progression when bevacizumab (Avastin) was added to niraparib (Zejula), a phase II study found.… Read more

Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells

May 15, 2019 6:00 pm

According to researchers at Yale Cancer Center, a cancer drug thought to be of limited use possesses a superpower of sorts: It is able to stop certain cancer cells from repairing their DNA in order to survive. The study, published … Read more

Study Shows Ovarian Cancer Survival Increase

May 3, 2019 5:00 pm

A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult … Read more

6 Questions to Ask Your Doctor After an Ovarian Cancer Diagnosis

April 30, 2019 5:00 pm

Two of the key points this article touches on refer to finding a clinical trial and seeking mental health support. At Clearity, we can help! Check out our Clinical Trial Finder, as well as Steps Through OC, a Read more

Impact of Somatic Molecular Profiling on Clinical Trial Outcomes in Rare Epithelial Gynecologic Cancer Patients

April 25, 2019 6:00 pm

Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic

Read more

Still No Benefit of IP Chemo for Ovarian Cancer

April 24, 2019 5:00 pm

By Charles Bankhead

No PFS or OS benefit, more toxicity with IP verses IV regimens

Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more

Niraparib Offers New Option in Heavily Pretreated Ovarian Cancer

April 17, 2019 7:00 pm

By Dave Levitan

Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.

“Although most … Read more